rs7799039 — LEP G-2548A

Promoter variant that increases leptin gene expression in adipose tissue, elevating circulating leptin and raising obesity, insulin resistance, and metabolic syndrome risk

See your personal result for LEP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Leptin Promoter Variant That Amplifies Your Fat-Signaling Thermostat

Leptin is the hormone adipose tissue sends to the hypothalamus to announce that energy stores are adequate — its central function is to suppress appetite and increase energy expenditure when fat stores are full. The G-2548A polymorphism (rs7799039) sits in the promoter region of the LEP gene, 2,548 base pairs upstream of the translation start site, at a regulatory position that controls how actively the gene is transcribed. Carriers of the A allele make more leptin — but chronic overproduction of any hormone typically leads to receptor desensitization, and that is precisely where this variant's metabolic consequences unfold.

The LEP gene sits on chromosome 7 (7q32.1) on the plus strand. The G-2548A variant is a straightforward G-to-A transition in the promoter; it does not change the leptin protein itself but alters how much of it is produced by fat cells.

The Mechanism

A landmark 2002 study by Hoffstedt et al.11 Hoffstedt et al.
"A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin." Obesity Research, 2002 demonstrated the functional consequence directly in human adipose tissue. In 39 non-obese women, AA homozygotes showed:

  • 60% higher leptin mRNA in adipose tissue (74 vs 46 amol/μg RNA, p=0.01)
  • Twice the adipose leptin secretion rate (1,158 vs 626 ng per 2h per 10⁷ cells, p=0.02)
  • 50% higher serum leptin (14.5 vs 9.7 ng/ml, p=0.02)

These differences remained significant after adjusting for BMI, confirming they reflect genetically driven differences in transcriptional activity rather than adiposity. The mechanism involves nuclear proteins forming stronger protein-DNA complexes with the -2548A variant, enhancing transcription factor binding and boosting promoter activity.

Chronically elevated leptin — hyperleptinemia22 hyperleptinemia
Persistently high leptin levels that cause the hypothalamic leptin receptor to downregulate, blunting the satiety signal — leads to leptin resistance. This paradox (high leptin, inadequate signal) mirrors insulin resistance: the hormone is abundant but tissues stop responding. The downstream consequences include impaired satiety signaling, increased food intake, and reduced energy expenditure — the metabolic triad that promotes obesity.

The Evidence

Metabolic outcomes: Multiple studies link the A allele to adverse metabolic profiles. In a Malaysian cohort of 300 subjects, AA genotype carriers with T2DM33 AA genotype carriers with T2DM
Ali et al. 2022, LEP G2548A polymorphism associated with leptin and insulin resistance in Malaysian T2DM patients showed significantly higher BMI, serum leptin, and fasting insulin compared to GG carriers. A systematic review and pooled analysis of 18,984 subjects across 11 studies44 18,984 subjects across 11 studies
Khaki-Khatibi et al. 2022, Gene polymorphism of leptin and risk for heart disease, obesity, and high BMI concluded that AA allele carriers face increased risk for heart disease, high BMI, and obesity.

Diet response: The A allele markedly blunts lipid improvement with dietary intervention. In 122 obese patients55 122 obese patients
Primo et al. 2021, Leptin gene polymorphism rs7799039 associated with lipid profile changes on hypocaloric diet randomized to a partial meal-replacement hypocaloric diet, GG carriers reduced triglycerides by 15.3 mg/dL while GA/AA carriers reduced them by only 3.7 mg/dL — a four-fold difference. Total cholesterol fell 25.0 mg/dL in GG vs 8.1 mg/dL in A-allele carriers; LDL fell 20.7 vs 5.4 mg/dL.

Lipids during pregnancy: A prospective Brazilian cohort study of 154 pregnant women66 154 pregnant women
Farias et al. 2020, rs7799039 associated with serum lipid concentrations during pregnancy found AA genotype carriers reported higher fat and total energy intake and had greater triglyceride increases throughout pregnancy. Importantly, adjusting for dietary fat intake did not eliminate the genotype-lipid association, suggesting a direct genetic effect on lipid metabolism beyond behavioral differences.

Cancer association: A meta-analysis of 31 case-control studies with 25,799 subjects77 31 case-control studies with 25,799 subjects
Tang et al. 2019, Leptin rs7799039 polymorphism and cancer risk meta-analysis found A-allele carriers had OR 1.16–1.22 for overall cancer susceptibility, with elevated risk for prostate cancer (OR 1.24) and hematopoietic malignancies in Asian populations.

Note on evidence inconsistency: Population studies show heterogeneous results — some find no association between G2548A and obesity or BMI in isolation, particularly in Turkish and some European cohorts. The strongest and most consistent signals come from mechanistic studies (adipose tissue directly), obese clinical cohorts, and dietary intervention trials. The evidence is moderate, not established.

Practical Actions

For GG genotype carriers, standard dietary advice applies — no genotype-specific modification is needed. For A allele carriers (AG and AA), the primary implication is that standard caloric restriction produces blunted lipid improvements compared to GG individuals, and chronically elevated leptin production sets up a physiological context favoring leptin resistance. Limiting dietary saturated fat and refined carbohydrates specifically targets the triglyceride and insulin sensitivity pathways most affected by this variant. For AA homozygotes, the effect is dose-dependent and warrants closer monitoring of fasting triglycerides, glucose, and insulin.

Interactions

The most studied interaction involves LEP G2548A combined with LEPR Q223R (rs1137101). A Tunisian study of 329 subjects found that the combined haplotype carrying the 2548A allele and LEPR 223R (AR haplotype) increased obesity risk to OR 3.36 (p<0.001), substantially higher than either variant alone. The 2548A + 223Q haplotype also raised obesity risk (OR 2.56, p=0.010). This interaction makes biological sense: elevated leptin production (LEP A allele) combined with impaired receptor binding (LEPR R allele at position 223) compounds both branches of the leptin signaling circuit simultaneously.

A second LEP promoter variant, rs2167270 (G-19A), has been studied in combination with rs7799039. These two LEP promoter variants can combine in haplotypes that affect leptin levels and metabolic syndrome markers, though the interaction evidence is less robust than for LEP-LEPR combinations.

Nutrient Interactions

dietary fat altered_metabolism
total energy increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Leptin Production Normal

Normal leptin promoter activity with standard adipose signaling

You carry two copies of the ancestral G allele, the most common form in African and European populations. Your adipose tissue produces leptin at baseline levels, with no genetically elevated transcriptional drive. This genotype is associated with normal leptin-hypothalamus signaling and is less predisposed to leptin-driven obesity and insulin resistance. Approximately 48% of people globally share this genotype, rising to roughly 83% in African-ancestry populations where the A allele is rare.

AG Elevated Leptin Production Intermediate

One copy of the promoter variant raising leptin production in adipose tissue

The A allele creates a stronger protein-DNA complex at the -2548 position, boosting leptin promoter activity. As a single copy, the effect is intermediate. Chronically elevated leptin can progressively downregulate hypothalamic leptin receptor sensitivity, potentially blunting satiety signaling over time — particularly in the context of a high-fat, high-calorie dietary pattern. Studies in obese cohorts consistently show heterozygotes have intermediate metabolic risk between GG and AA carriers. Lipid responses to calorie-restricted diets are approximately 50-60% as robust as in GG carriers.

AA High Leptin Production High Risk

Two copies of the promoter variant producing elevated leptin and increasing insulin resistance and metabolic syndrome risk

Mechanistically, the AA genotype amplifies leptin transcription through stronger nuclear protein binding at the -2548 promoter site. Serum leptin is approximately 50% higher in non-obese AA women compared to GG/GA carriers — before obesity even develops. In obese individuals, this genetic baseline amplification compounds adiposity-driven hyperleptinemia further. Hyperleptinemia triggers receptor desensitization in the hypothalamus, pancreatic beta cells, and peripheral tissues expressing leptin receptors, cascading into impaired glucose homeostasis.

Clinical studies show AA carriers with type 2 diabetes have significantly higher BMI, serum leptin, and fasting insulin compared to GG counterparts, with a 5.1-fold increased T2DM risk in some cohorts vs GG (GA = 2.6-fold). The dietary response is substantially blunted: in caloric restriction trials, GG carriers improved triglycerides by 15.3 mg/dL vs only 3.7 mg/dL in A-allele carriers — a four-fold gap. A systematic review of 18,984 subjects confirmed AA allele carriers face elevated risk for heart disease, high BMI, and obesity. The evidence is consistent in obese clinical cohorts and in mechanistic tissue studies, but heterogeneous in population-level studies — hence a moderate rather than strong evidence rating.